The Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor offers a right to option and evaluation the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all option and evaluation deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both pure option and evaluation deals and multicomponent deals where option and evaluation forms a part.

Chapter 4 provides a review of the leading option and evaluation deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of option and evaluation deals signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.

In addition the report includes a series of appendices containing a comprehensive listing of all option and evaluation deals announced since 2009.

Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous tables and figures that illustrate the trends and activities in option and evaluation dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.

Table Of Contents

Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in option and evaluation dealmaking
2.1. Introduction
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2009
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon - Ception - January 2009
2.6.2. Case study 2: Endo - Indevus - January 2009
2.6.3. The future of option to acquire deals

Chapter 3 - Overview of option and evaluation deal structure

3.1. Introduction
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: Idenix Pharmaceuticals - Janssen Pharmaceuticals - January 2013
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec - Isis Pharmaceuticals - June 2012
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis -Prometheus - January 2010
3.3.1.c. Option to finance
Case study 6: Amarantus BioSciences- Power3 Medical Products - January 2012
3.3.1.d. Option to co-promote
Case study 7: Teva - OncoGenex Pharmaceuticals - December 2009
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix - Nycomed - July 2007
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: ViroPharma- Meritage Pharma - December 2011
3.4.1.b. Case study 10: Nuvasive - Progentix Orthobiology - January 2009

Chapter 4 - Leading option and evaluation deals

4.1. Introduction
4.2. Top option and evaluation deals by value
4.3. Most active option and evaluation dealmakers
4.4. Big pharma option and evaluation deal activity
4.5. Big biotech option and evaluation deal activity

Chapter 5 - Big pharma option and evaluation deals

5.1. Introduction
5.2. How to use option and evaluation deals
5.3. Big pharma company option and evaluation deal profiles
Abbott
Abbvie
Actavis
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Gilead Sciences
GlaxoSmithKline
Grifols
Johnson and Johnson
Kyowa Hakko Kirin
Lundbeck
Merck and Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Otsuka
Pfizer
Purdue
Roche
Sanofi
Servier
Shire
Takeda
Teva
UCB
Valeant

Chapter 6 - Big biotech option and evaluation deals

6.1. Introduction
6.2. How to use big biotech partnering deals
6.3. Big biotech option and evaluation partnering company profiles
Alexion Pharmaceuticals
Biocon
BioMarin Pharmaceuticals
Cubist
Dendreon
Emergent BioSolutions
Galapagos
Genmab
Ipsen
Isis Pharmaceuticals
LFB Group
Morphosys
Regeneron Pharmaceuticals
Salix Pharmaceuticals
Seattle Genetics
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
Vertex Pharmaceuticals

Chapter 7 - Option and evaluation contracts directory

7.1. Introduction
7.2. Option and evaluation deals by company A-Z
Abbvie
ACADIA Pharmaceuticals
Acceleron Pharma
Achaogen
Adeona Pharmaceuticals
Adimab
Agensys
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alimera Sciences
Alseres Pharmaceuticals
Amarantus BioSciences
Ambit Biosciences
Ambrx
Amgen
Amylin Pharmaceuticals
Amyris Biotechnologies
Anesiva
Aquamer Medical
Aradigm
Ardelyx
Ariad Pharmaceuticals
Arno Therapeutics
Array Biopharma
Aslan Pharma
Astellas Pharma
AstraZeneca
Athersys
Atlantic Healthcare
Avalanche Biotechnologies
AVEO Pharmaceuticals
Avery Dennison
Avimex
Basilea Pharmaceutica
Bayer
Bayer Schering Pharma
Baylor Research Institute
BIND Biosciences
BIND Therapeutics
BioAxone Therapeutic
BioCryst Pharmaceuticals
Biogen Idec
BioMarin Pharmaceutical
Biomedical Advanced Research and Development Authority
Biosara
Biovail
Boehringer Ingelheim
Bristol-Myers Squibb
Cadila Pharmaceuticals
Cardigant Medical
Cardiome Pharma
Cedars-Sinai Medical Center
Celgene
Cell Cure Neurosciences
ChemoCentryx
Cleveland BioLabs
Clovis Oncology
Colloral
Cortex Pharmaceuticals
CPL Biologicals
Crucell
Cryolife
Cytokinetics
Cytori Therapeutics
Dainippon Sumitomo Pharma
Dendreon
Department of Defense
Department of Health and Human Services
Department of Homeland Security
Dicerna Pharmaceuticals
Dow AgroSciences
Dyax
Dynavax Technologies
Eli Lilly
Embryome Sciences
Emergent BioSolutions
Emory University
EndoStim
Enterome Bioscience
EPIX Pharmaceuticals
Evotec
Exelixis
Fluidigm
Forest Laboratories
Fovea Pharmaceuticals
Furiex Pharma
Futurebiotics
Galderma
Galmed Pharmaceuticals
Genentech
GenVec
Genzyme
GlaxoSmithKline
GlobeImmune
GlycArt
Grifols
Hadasit Bioholdings
Hadassah University
Heat Biologics
IBM
Idenix Pharmaceuticals
ImmunoCellular Therapeutics
Immunovative Therapies
Incyte
Infinity Pharmaceuticals
Intellect Neurosciences
Intellikine
Intercept Pharmaceuticals
Intervet
Intrexon
Invivis Pharmaceuticals
Isis Pharmaceuticals
Ivax
Janssen Pharmaceutica NV
Janssen Pharmaceuticals
JDRF
KaloBios Pharmaceuticals
Krele Pharmaceuticals
Kyowa Hakko Kirin
La Jolla Pharmaceutical
LFB Biotechnologies
Ligand Pharmaceuticals
Lipocine
Lpath
Lumena Pharmaceuticals
Macrogenics
Manhattan Scientifics
Maxygen
MDRNA
Medicis Pharma
Medtronic
Melinta Therapeutics
Memory Dx
Merck and Co
Merck Serono
Merck Sharpe and Dohme
Merial
Meritage Pharma
Merrimack Pharmaceuticals
Metabasis Therapeutics
Micromet
Millennium
Mundipharma
National Cancer Institute
National Institute of Diabetes and Digestive and Kidney Diseases
NeurogesX
NovaBay Pharmaceuticals
Novartis
Novartis Vaccines and Diagnostics
Novavax
Novelos Therapeutics
Novo Energies
NuVasive
Oceana Therapeutics
Oculus Innovative Sciences
OncoGenex Pharmaceuticals
Opexa Therapeutics
OPKO Health
Oregon Health Sciences University
Ortho-McNeil
OSI Pharmaceuticals
Peregrine Pharmaceuticals
PerkinElmer
Perseid Therapeutics
Pfizer
Pharmacopeia
Power3 Medical Products
PPD
Procter and Gamble
Progentix Orthobiology
Prometheus Laboratories
Psynova Neurotech
Purdue Pharma
Quark Pharmaceuticals
Quick Med Technologies
Receptos
Regen BioPharma
Regeneron Pharmaceuticals
Regulus Therapeutics
Reproductive Genetics Institute
Revance Therapeutics
REVO Biologics
Rexahn Pharmaceuticals
Roche
Ruthigen
Sagent Pharmaceuticals
Sangamo BioSciences
Sanofi-Aventis
Sanofi-Pasteur
Sanofi
Schering-Plough
Schering AG
Scientific Nanomedicine
Seattle Genetics
Senior Scientific
Servier
Somaxon Pharmaceuticals
Spectrum Pharmaceuticals
Starch Medical
Stason Pharmaceuticals
SuperGen
Symphony Allegro
Symphony Dynamo
Takeda Pharmaceutical
Targacept
Tengion
TerraSphere Systems
Tesaro
Teva Pharmaceutical Industries
TopoTarget
Total Gas and Power USA Biotech
Transcept Pharmaceuticals
Transition Therapeutics
Tranzyme Pharma
Trevena
TrovaGene
Ultragenyx Pharmaceuticals
University of Cambridge
University of Miami
University of Michigan
University of Southern Carolina
Urigen
Valeant Pharmaceuticals
Vanda Pharmaceuticals
Vical
Viropharma
Vitae Pharmaceuticals
Waratah Pharmaceuticals
Xencor
Xenon Pharmaceuticals
Xenoport
Xoma
Yeugnam University
Zoetis
ZymoGenetics

7.3. Option and evaluation deals by stage of development

Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory

7.4. Option and evaluation deals by therapeutic target

Anaesthetics
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Public health
Respiratory

7.5. Option and evaluation deals by technology type

Analysis
Antibiotics
Antibodies
Assays
Biodefense
Biological compounds
Biomarkers
Biomaterials
Blood products
Cell culture
Clinical testing
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Enviromental
Epigenetics
Gene therapy
Genomics
Implant
Nanotechnology
Natural product
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Regenerative medicine
Research services
RNA therapeutics
Screening
Small molecules
Software tools
Vaccines

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Reports

TABLE OF FIGURES
Figure 1: Definition of option and evaluation deals
Figure 2: Types of option right
Figure 3: Trends in option and evaluation deal announcements, 2009-2014
Figure 4: Recent option-based deals
Figure 5: Example deals where co-promotion options have been actively exercised, since 2000
Figure 6: Recent ‘option to acquire’ deals
Figure 7: Components of the option and evaluation deal structure
Figure 8: Types of option in an agreement
Figure 9: Attributes of option terms:
Figure 10: Top option and evaluation deals by value since 2009
Figure 11: Most active option and evaluation dealmakers 2009-2014
Figure 12: Big pharma - top 50 - option and evlaution deals 2009 to 2014
Figure 13: Big pharma option and evaluation deal frequency - 2009 to 2014
Figure 14: Big biotech - top 50 - option and evaluation deals 2009 to 2014
Figure 15: Big biotech option and evaluation deal frequency - 2009 to 2014

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

Future Horizons and Growth Strategies in the Global Microbiology Testing Market 2014: Supplier Shares and Country Forecasts

  • $ 21 100
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $32,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100. “2014 Strategies for the Global Microbiology Testing Market” is a new seven-country strategic analysis ...

Future Horizons and Growth Strategies in the Global Diagnostic Imaging Market 2014: Strategic Assessments of Leading Suppliers

Future Horizons and Growth Strategies in the Global Diagnostic Imaging Market 2014: Strategic Assessments of Leading Suppliers

  • $ 14 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $14,500.  Individual company assessments $2,450.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...

Future Horizons and Growth Strategies in the Global Ultrasound Market 2014: Strategic Assessments of Leading Suppliers

Future Horizons and Growth Strategies in the Global Ultrasound Market 2014: Strategic Assessments of Leading Suppliers

  • $ 12 500
  • Industry report
  • August 2014
  • by Venture Planning Group

Complete report $12,500.  Individual company assessments $1,850.  The report is available by company, section, market segment, and can be custom-tailored to your specific information needs and budget. ...


1 Companies

Company Profiles

Seattle Genetics Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.